Literature DB >> 25925285

A cautionary note on the immunohistochemical detection of BRAF v600e mutations in serrated lesions of the colon.

Nicole C Panarelli1, Anna-Sophie Weidner1, Rhonda K Yantiss1, Yao-Tseng Chen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25925285     DOI： 10.1038/modpathol.2014.112

Source DB:  PubMed          Journal:  Mod Pathol        ISSN： 0893-3952            Impact factor:   7.842


× No keyword cloud information.
  9 in total

1.  BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.

Authors:  Kajsa Affolter; Wade Samowitz; Sheryl Tripp; Mary P Bronner
Journal:  Genes Chromosomes Cancer       Date:  2013-05-07       Impact factor: 5.006

2.  Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.

Authors:  Frank A Sinicrope; Thomas C Smyrk; David Tougeron; Stephen N Thibodeau; Shalini Singh; Andrea Muranyi; Kandavel Shanmugam; Thomas M Grogan; Steven R Alberts; Qian Shi
Journal:  Cancer       Date:  2013-05-08       Impact factor: 6.860

3.  Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.

Authors:  Ildiko Mesteri; Günther Bayer; Jochen Meyer; David Capper; Sebastian F Schoppmann; Andreas von Deimling; Peter Birner
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

4.  High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.

Authors:  Kevin J Spring; Zhen Zhen Zhao; Rozemary Karamatic; Michael D Walsh; Vicki L J Whitehall; Tanya Pike; Lisa A Simms; Joanne Young; Michael James; Grant W Montgomery; Mark Appleyard; David Hewett; Kazutomo Togashi; Jeremy R Jass; Barbara A Leggett
Journal:  Gastroenterology       Date:  2006-08-18       Impact factor: 22.682

5.  Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.

Authors:  Michael J O'Brien; Shi Yang; Charline Mack; Huihong Xu; Christopher S Huang; Elizabeth Mulcahy; Mark Amorosino; Francis A Farraye
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

6.  Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.

Authors:  Shih-Fan Kuan; Sarah Navina; Kristi L Cressman; Reetesh K Pai
Journal:  Hum Pathol       Date:  2013-11-04       Impact factor: 3.466

7.  Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.

Authors:  Cheryl A Adackapara; Lynette M Sholl; Justine A Barletta; Jason L Hornick
Journal:  Histopathology       Date:  2013-06-13       Impact factor: 5.087

8.  Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.

Authors:  Paul Lochhead; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Mai Yamauchi; Reiko Nishihara; Zhi Rong Qian; Teppei Morikawa; Jeanne Shen; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  J Natl Cancer Inst       Date:  2013-07-22       Impact factor: 13.506

Review 9.  Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention.

Authors:  Dora Colussi; Giovanni Brandi; Franco Bazzoli; Luigi Ricciardiello
Journal:  Int J Mol Sci       Date:  2013-08-07       Impact factor: 5.923
  9 in total
  1 in total

Review 1.  Colonic perineurioma (benign fibroblastic polyp): case report and review of the literature.

Authors:  Abraham Christoffel van Wyk; Hennie van Zyl; Jonathan Rigby
Journal:  Diagn Pathol       Date:  2018-02-20       Impact factor: 2.644
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.